-

01:59:03 PM

INCY Stock News

INCY - Incyte Corp.

08/03/21 7:00 AM

Nasdaq : INCY

earnings

Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (Nasdaq:INCY) today reports 2021 second quarter financial results and provides a status update on the Company’s development portfolio.“In the second quarter, we saw an acceleration of growth of Jakafi ® (ruxolitinib) and encouraging uptake in Europe for Pemazyre ® (pemigatinib). In

RHEA-AI

neutral

08/03/21 6:00 AM

NYSE, Nasdaq : LLY, INCY

covid-19

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane

RHEA-AI

negative

07/23/21 4:30 PM

Nasdaq : INCY

Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, for the treatment of adult patients with locally advanced

RHEA-AI

neutral

07/15/21 8:00 AM

Nasdaq : INCY

conferencesearnings

Incyte to Report Second Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 3, 2021.The schedule for the press release and conference call/webcast is as follows:• Q2 2021 Press Release:August 3, 2021 at 7:00

RHEA-AI

neutral

07/14/21 5:00 PM

Nasdaq : INCY

clinical trial

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi ®) resulted in significantly improved outcomes in patients with steroid-refractory or

RHEA-AI

neutral

06/25/21 7:42 AM

Nasdaq : INCY, MOR

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization of tafasitamab in combination with lenalidomide,

RHEA-AI

very positive

06/24/21 3:30 PM

Nasdaq : INCY

Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte (Nasdaq:INCY) today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which reviewed the Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult

RHEA-AI

very positive

06/12/21 5:01 PM

Nasdaq : INCY

Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis (AD) will be presented at the upcoming 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference,

RHEA-AI

neutral

06/11/21 7:30 AM

Nasdaq : INCY

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) action date has been

RHEA-AI

neutral

06/08/21 7:30 AM

Nasdaq : INCY

Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi ®) for the treatment of adult and pediatric patients 12 years and older with steroid-refractory chronic

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 8 9 Next